Brokerages Set MiMedx Group, Inc. (NASDAQ:MDXG) PT at $12.00

MiMedx Group, Inc. (NASDAQ:MDXG) has received an average recommendation of “Buy” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $12.00.

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th.

MiMedx Group Trading Down 1.1 %

NASDAQ MDXG opened at $9.57 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of 17.40 and a beta of 1.98. The company’s 50-day simple moving average is $7.28 and its two-hundred day simple moving average is $6.95. MiMedx Group has a one year low of $5.47 and a one year high of $9.73.

Hedge Funds Weigh In On MiMedx Group

Institutional investors have recently made changes to their positions in the company. Isthmus Partners LLC increased its holdings in MiMedx Group by 30.4% in the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after acquiring an additional 91,714 shares in the last quarter. Blue Trust Inc. purchased a new stake in MiMedx Group in the 3rd quarter worth $30,000. Point72 Asset Management L.P. purchased a new stake in MiMedx Group in the 2nd quarter worth $40,000. Point72 DIFC Ltd increased its holdings in MiMedx Group by 127.6% in the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after acquiring an additional 4,275 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in MiMedx Group in the 3rd quarter worth $64,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.